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Gingival crevicular ﬂuidAbstract Background: Matrix metalloproteinase-1 (MMP-1) is a member of a family of enzymes
that can degrade most extracellular matrix macromolecules. Extracellularly, MMPs are controlled
by tissue inhibitors of metalloproteinases (TIMPs) and by mechanisms of pro-MMP activation.
Levels of MMPs and TIMPs change during healing, inﬂammation, and normal tissue turnover.
Herein we aimed to evaluate the levels of MMP-1 and TIMP-1 in gingival crevicular ﬂuid (GCF)
from periodontally healthy patients (control group) and chronic periodontitis patients before and
after phase 1 therapy.
Methods: In this study we examined 30 patients who had chronic periodontitis with probing
depth sites P5 mm and a clinical attachment level (CAL) P5 mm. We included 30 periodontally
healthy patients as a control. Clinical measurements such as plaque (PI) and gingival (GI) indices,
papillary bleeding index (PBI), probing depths (PD), and CAL were recorded both before treatment
(BT) and after phase I periodontal treatment (AT). Assays for MMP-1 and TIMP-1 were performed
with an enzyme-linked immunosorbent assay (ELISA) method.
Results: All clinical parameters were signiﬁcantly reduced at the post-therapy visit. MMP-1 lev-
els were signiﬁcantly higher in patients BT than the controls; however, the patients AT were not
statistically different than the controls. TIMP-1 levels in patients BT were signiﬁcantly lower than
172 P.S. Ghodpage et al.in the controls and signiﬁcantly lower than patients AT. We observed a signiﬁcant positive corre-
lation between GCF volume and MMP-1 levels. Furthermore, TIMP-1 levels were signiﬁcantly neg-
atively correlated with both GCF volume and all clinical parameters.
Conclusions: We observed that as the extent of periodontal destruction increases, MMP-1 con-
centration increases and TIMP-1 concentration decreases in GCF. When chronic periodontitis
patients were treated by scaling and root planing (SRP), the average MMP-1 concentrations
decreased and TIMP-1 concentrations increased in GCF.
ª 2014 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Periodontitis is an infectious disease characterized by peri-
odontal attachment loss, bone destruction, and eventually
tooth loss (Socransky and Haffajee, 1992). The tissue destruc-
tion appears to result from a complex interaction between bac-
teria and the host immune system and a complex network of
cytokines, prostaglandins, reactive oxygen species, and proteo-
lytic enzymes. Matrix metalloproteinases (MMPs) are a genet-
ically distinct but structurally related family of host-derived
proteolytic enzymes involved in the physiological and patho-
logical degradation of extracellular matrix and basement mem-
brane proteins (Birkedal-Hansen, 1993). To date, 24 different
MMPs have been cloned and 23 of those are found in humans.
Fibrillar collagens are resistant to most proteinases and
have the potential to initiate collagenolysis during periodontal
inﬂammation. MMP-1, or interstitial collagenase, is one of the
key proteolytic enzymes that degrade ﬁbrillar collagens, espe-
cially types I and III, which are the predominant types of inter-
stitial collagens in gingiva. MMP-1 is expressed by ﬁbroblasts,
endothelial cells, macrophages, hepatocytes, chondrocytes,
osteoblasts, tumor cells, and migrating epidermal keratino-
cytes, but not neutrophils (Birkedal-Hansen, 1993). Tissue
inhibitors of metalloproteinases (TIMPs) regulate the proteo-
lytic activity of MMPs. For example, TIMP-1 effectively inhib-
its the activity of interstitial collagenase, such as MMP-1
(Shibata et al., 1991). TIMPs are expressed by many cells,
including ﬁbroblasts, keratinocytes, monocytes, macrophages,
endothelial cells, and osteoblasts. There are four identiﬁed
types of TIMPs, TIMP-1, -2, -3, and -4, which are widely dis-
tributed in oral and body ﬂuids. The correct balance of MMPs
and TIMPs is critical to degrade the connective tissue matrix
under both physiological and pathological conditions. Thus,
it is important to study the relationship between MMPs and
TIMPs, as they reﬂect the status of periodontal diseases. The
present study aimed to study MMP-1 and TIMP-1 levels in
healthy patients and chronic periodontitis patients. Further,
we examined the effect of phase 1 therapy on MMP-1 and
TIMP-1 levels.
2. Materials and methods
2.1. Study population
A total of 60 subjects between 25 and 55 years of age were
selected from patients visiting the Department of Periodontics
of Vidya Shikshan Prasarak Mandal Dental College and
Research Centre, Nagpur, India. These patients were assessed
clinically and biochemically. All protocols were cleared by theInstitutional Ethics Committee of our institute. We designed a
survey to allow systematic recording of information and obser-
vations. The survey included a detailed case history, clinical
examination, periodontal indices, and the patient’s written
consent. The study comprised of two groups: group I, a con-
trol group of 30 periodontally healthy subjects, and group II,
a test group of 30 patients with chronic periodontitis who were
assessed before therapy (BT) and after phase 1 therapy (AT) –
It included oral hygiene instructions and scaling and root plan-
ing. Patients were considered healthy if they exhibited a prob-
ing depth <3 mm and there was no clinical attachment loss
(CAL). The average age of this group was 35.13 ± 7.14.
Patients were diagnosed with chronic periodontitis if they
exhibited a probing pocket depth P5 mm and CAL P5 mm
at multiple sites. The average age of this group was
29.6 ± 4.84 years. All subjects were generally in good health
and none had received periodontal treatment or medication
during the past 6 months. No participants had a history of sys-
temic conditions such as heart disease, diabetes, or other disor-
ders that could inﬂuence the course of periodontal disease.
Patients were not on any medication that could affect the man-
ifestations of periodontal disease such as antibiotics, or their
use in the 6 months prior, phenytoin, cyclosporine, anti-
inﬂammatory drugs, or calcium channel blockers. Postmeno-
pausal women and smokers were excluded from the study.
The clinical evaluation of patients was based on the follow-
ing indices: plaque index (PI) (Silness & Loe, 1964), gingival
index (GI) (Loe & Silness, 1963), probing depths (PD), CAL,
and papillary bleeding index (Muhlemann, 1977). All parame-
ters, which were recorded for the complete dentition, were
measured using a Williams probe calibrated in mm. The most
severely affected upper anterior sextant (maxillary incisors and
the canine teeth) was chosen for collection of gingival crevicu-
lar ﬂuid (GCF). GCF sampling and clinical index scores were
recorded at baseline before treatment and 6 weeks after phase I
periodontal therapy. All patients underwent therapy including
oral hygiene instruction, scaling, root planning, and gingival
curettage under local anesthesia.2.2. GCF sampling and processing
All of the patients were informed about the procedure and
were seated comfortably in the dental chair. Prior to GCF col-
lection, the supragingival soft deposits were removed without
causing trauma to the gingival crevice. If hemorrhage was evi-
dent after this procedure the GCF was not collected from that
site. GCF samples were collected from 13 to 23 regions because
the regions were easy to isolate and salivary contamination
could be avoided. A microcapillary pipette was used to collect
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water, isolated by cotton rolls, and dried by stream of air. Suc-
tion was also used frequently to aspirate saliva to avoid GCF
contamination. In subjects with clinically healthy gingiva, a
ring of clear GCF was seen 15–20 min after the isolation of
maxillary teeth at the gingival margin and interdental areas.
In chronic gingivitis and chronic periodontitis patients, the
clear ring of GCF could easily be seen after 5–10 min. The
microcapillary pipette was then placed extracrevicularly in
the accumulated ﬂuid, and the GCF was collected in the micro-
capillary tube. Approximately 10 ll of GCF was collected
from patients with chronic periodontitis and 4–5 ll of GCF
was collected from patients with healthy gingiva. The samples
were stored for a maximum time of 24 h at 20 C before
analysis.
2.3. Estimation of MMP-1 and TIMP-1 levels using ELISA
We used a Ray Bio (Ray Biotech, Inc., USA) Human MMP-
1 and TIMP-1 Enzyme Linked Immunosorbent Assay
(ELISA). This kit is an in vitro ELISA that quantitatively mea-
sures human MMP-1 and TIMP-1 in serum, plasma, cell cul-
ture supernatants, and urine. This assay uses human speciﬁc
MMP-1 and TIMP-1 antibodies coated on a 96-well plate.
Standards and samples were pipetted into the wells, and the
MMP-1 and TIMP-1 bound to the wells through the immobi-
lized antibody. The wells were washed and biotinylated anti-
human MMP-1 and TIMP-1 antibodies were added. After
washing to remove unbound biotinylated antibody, we pipet-
ted HRP-conjugated streptavidin into the wells. The wells were
washed, and subsequently, a Tetra methylbenzidine (TMB)
substrate solution was added to the wells. Color developed
in proportion to the amount of MMP-1 and TIMP-1 bound
to the well. The stop solution changed the color from blue to
yellow, and the color intensity was measured at 450 nm.
MMP-1 and TIMP-1 concentrations were determined using a
standard curve.2.4. Statistical analysis
Statistical analysis was done using STRATA software version
10.0. Clinical parameters such as PD, CAL, PI, GI, and pap-
illary bleeding index, and MMP-1and TIMP-1 levels were cal-
culated for non normalized data. Paired ‘t’ tests were
performed to compare BT and AT for all parameters. BT
and AT were compared with control using an unpaired ‘t’ test.
A correlation coefﬁcient (r) was calculated to assess the rela-
tionship between clinical parameters and MMP-1 or TIMP-
1. A p value <.05 was considered statistically signiﬁcant.3. Results
For all clinical parameters we observed a statistically signiﬁcant differ-
ence between BT patients and the control group and between AT
patients and their control group. Additionally, all of the clinical
parameters were signiﬁcantly reduced from BT to AT. MMP-1 levels
were signiﬁcantly higher BT compared to the control subjects, but
MMP-1 levels were not signiﬁcantly different between patients AT
compared to the control group. Finally, AT patients had signiﬁcantly
lower MMP-1 levels than BT patients. We noted a signiﬁcant positive
correlation between GCF volume and MMP-1 levels.TIMP-1 levels were signiﬁcantly higher in the control group than in
patients BT, and TIMP-1 levels were also signiﬁcantly higher AT than
BT. We also observed a signiﬁcant difference in TIMP-1 levels between
AT patients and the control group. Finally, TIMP-1 was signiﬁcantly
negatively correlated with GCF volume and all clinical parameters.
4. Discussion
Periodontal diseases are characterized by a loss of extracellular
matrix constituents, such as collagen ﬁbers, in periodontal tis-
sues. A possible mechanism for periodontal extracellular
matrix degradation is the independent and/or cooperative
action of human and bacterial proteinases (Sorsa et al.,
1992). It is likely that a signiﬁcant portion of periodontal tissue
destruction is mediated by a host of cell-derived MMPs. There
are four known mechanisms that regulate MMP functional
activity: (1) positive and negative transcriptional controls of
MMP genes; (2) the activation from a latent state; (3) differ-
ences in substrate speciﬁcity; and (4) modulation by serum
inhibitors or TIMPs (Birkedal-Hansen, 1993).
A number of studies have suggested that osteoblasts express
ﬁbroblast collagenase when stimulated by bone-resorbing
agents (Otsuka et al., 1984; Civitelli et al., 1989). MMP-1 is
expressed by osteoblasts in response to resorptive signals such
as parathyroid hormone. This leads to the initiation of osteo-
clastic bone resorption, which in turn leads to degradation of
the unmineralized collagenous osteoid layer. Thus MMP-1
contributes to collagen degradation and bone resorption which
leads to worsening of periodontal disease. Ingman et al. (1996)
reported that MMP-1 is the predominant collagenase in the
GCF of patients with localized juvenile periodontitis. Further,
MMP-1 mRNA increases in inﬂammatory lesions of adult
patients with periodontitis (Aiba et al., 1996; Nomura et al.,
1993; Meikle et al., 1994). Thus, MMP-1 may also participate
in collagen degradation in advanced periodontal disease.
We found that MMP-1 levels are increased in patients with
chronic periodontitis compared to a healthy group, and MMP-
1 levels decrease after phase I therapy. TIMP-1 levels were
lower in patients with chronic periodontitis when compared
to a healthy group, and TIMP-1 levels increased signiﬁcantly
after phase I therapy. These results are in accordance with
results published by Tuter et al. (2002), who also investigated
the levels of MMP-1 and TIMP-1 before and after phase I
therapy.
Haerian et al. (1996) used a sandwich ELISA to evaluate
the effect of scaling and root planing on the levels of ﬁbroblast
collagenase, stromelysin, and TIMP in the GCF of patients
with advanced periodontal disease. They reported that TIMP
levels in GCF were signiﬁcantly increased after the phase I
therapy, and TIMP levels were signiﬁcantly reduced at the fol-
low-up visit 3 months later. Utilizing ELISA we found that
TIMP-1 levels were higher AT than BT; however, we measured
total enzyme, which includes both latent and active enzymes. It
is possible that post-treatment levels of active enzyme were
low.
There are several possible explanations for the increased
TIMP-1 levels we observed after periodontal therapy. We
observed a reduction in MMP-1, which if present would bind
to free TIMP; however, TIMP-1 regulation may not solely be
dependent on MMP-1 (Howard et al., 1991). Decreased
TIMP-1 levels in periodontally diseased patients may be due
to selective degradation of TIMP-1 by neutrophil elastase or
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Table B Correlation of levels of MMP-1 and TIMP-1 with
clinical parameters.
PD CAL PI GI PBI
MMP-1 r-Value 0.1139 0.0036 0.5321 0.4914 0.2399
p-Value 0.5489 0.9851 0.0025** 0.0058** 0.2016
TIMP-1 r-Value 0.2737 0.2512 0.2733 0.3614 0.0726
p-Value 0.1434 0.1802 0.0239* 0.0498* 0.7032
* P< 0.05 , Signiﬁcant.
** Highly signiﬁcant.0 
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Graph A Comparison of MMP-1 levels among study groups.
174 P.S. Ghodpage et al.the inactivation of TIMP-1 by neutrophils following oxidant
release (Okada et al., 1988). Phase I periodontal therapy may
have reduced the number of neutrophils and the elastaseTable A Comparison of clinical parameters, and GCF levels of
metalloproteinase (TIMP)-1 before and after therapy.
BT AT Con
MMP-1 (ng/ml) 3.98 3.13 2.7
TIMP-1 12.88 20.46 25.0
Pocket depth (mm) 4.50 3.35 2.1
Clinical attachment level (in mm) 4.71 3.57 2.1
Plaque index 4.14 2.48 2.1
Gingival index 1.97 1.34 0
* P< 0.05 - Signiﬁcant.released due to resolved gingival inﬂammation and tissue heal-
ing, thus resulting in increased TIMP-1 levels. Another possi-
bility is that the increased TIMP-1 levels reﬂect its
involvement in the healing process (Haerian et al., 1996). In
addition, there might be clearance of MMP-TIMP-1 com-
plexes by an as yet unidentiﬁed mechanism. Figueredo et al.
(2004) demonstrated that non-surgical treatment is effective
in both improving clinical parameters and reducing protease
activity in GCF of chronic periodontitis patients. Similar to
our study, both Kumar et al. (2013) and Tuter et al. (2005)
reported an increase in TIMP-1 levels after phase I therapy.
Soell et al. (2002) evaluated MMP and TIMP levels in GCF
and reported that MMP-1 levels were high in patients with
chronic periodontitis when compared to controls; whereas
TIMP-1 levels were lower in patients with chronic periodonti-
tis compared to controls. Tuter et al. (2005, 2007) reported
similar results. Haerian et al. (1996) pooled data from healthy,
gingivitis, and periodontitis sites and observed a moderately
positive, yet signiﬁcant, correlation between the biochemical
parameters, GCF, stromelysin, and TIMP levels with clinical
parameters.
We found a signiﬁcant, strong positive correlation between
MMP-1 levels and both PI and GI; whereas we found a signif-
icant strong negative correlation between TIMP-1 levels and
both PI and GI. These results indicate that the basis for divid-
ing patients into the two groups in our study was appropriate.
This result of our study is in accordance with Tuter et al.
(2005), who also reported a positive correlation between
MMP-1 levels and all the clinical parameters and a negative
correlation between TIMP-1 levels and all the clinical param-
eters. Similarly, Pozo et al. (2005) reported a signiﬁcant posi-
tive correlation between MMP and PD, CAL, and bleeding
on probing, and they reported that metalloproteinase has a
negative correlation with TIMP-1 levels. Notably, some stud-
ies have also found correlation between MMP-1 levels and
clinical parameters (Pozo et al., 2005 and Tuter et al., 2005),Matrix metalloproteinase (MMP)-1 and Tissue inhibitors of
trols BT vs AT BT vs control AT vs control
1 <0.001* <0.001* 0.1043*
1 <0.001* <0.001* 0.0214*
7 <0.001* <0.001* <0.001*
7 <0.001* <0.001* <0.001*
9 <0.001* <0.001* 0.0014*
<0.001* <0.001* 0.0014*
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tions can likely be attributed to the clinical inclusion criteria,
as clinical parameters do not necessarily reﬂect active peri-
odontal disease.
Here we report a higher ratio of MMP-1/TIMP-1 in
patients with chronic periodontitis BT, which is reduced AT.
These results are in accordance with previous studies (Tuter
et al., 2002; Mouzakiti et al., 2012). TIMPs have the widest
range of actions among all metalloproteinase inhibitors, and
they bind to most MMPs. Thus, the assessment of the
MMP-1/TIMP-1 ratios is important because an imbalance
between MMPs and TIMPs causes tissue degradation (Graphs
A–C, Tables A and B).5. Conclusion
We conclude that MMP-1 concentrations increase and TIMP-
1 concentrations decrease in GCF as periodontal destruction
becomes greater. After chronic periodontitis subjects are trea-
ted by Scaling and root planing, the average concentration of
MMP-1 reduces and the average concentration of TIMP-1
increases in GCF. However, further longitudinal studies are
needed to evaluate MMP-1 and TIMP-1 levels in periodontal
disease tissues.Conﬂict of interest
The authors hereby declare that there is no conﬂict of interest.
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